Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 625 to 629 of 629 entries
Sorted by: Best Match Show Resources per page
Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression.

Nucleic acids research

Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, Napierala JS, Napierala M.
PMID: 34718736
Nucleic Acids Res. 2021 Nov 18;49(20):11560-11574. doi: 10.1093/nar/gkab954.

Friedreich's ataxia (FRDA) is a severe multisystem disease caused by transcriptional repression induced by expanded GAA repeats located in intron 1 of the Frataxin (FXN) gene encoding frataxin. FRDA results from decreased levels of frataxin; thus, stabilization of the...

Cite
Li Y, Li J, Wang J, et al. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021;49(20):11560-11574doi: 10.1093/nar/gkab954.
Li, Y., Li, J., Wang, J., Lynch, D. R., Shen, X., Corey, D. R., Parekh, D., Bhat, B., Woo, C., Cherry, J. J., Napierala, J. S., & Napierala, M. (2021). Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic acids research, 49(20), 11560-11574. https://doi.org/10.1093/nar/gkab954
Li, Yanjie, et al. "Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression." Nucleic acids research vol. 49,20 (2021): 11560-11574. doi: https://doi.org/10.1093/nar/gkab954
Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, Napierala JS, Napierala M. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021 Nov 18;49(20):11560-11574. doi: 10.1093/nar/gkab954. PMID: 34718736; PMCID: PMC8599914.
Copy Download .nbib Format: NLM
Effect of Dexmedetomidine on Biochemical Recurrence in Patients after Robot-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Study.

Journal of personalized medicine

Yoo YC, Jang WS, Kim KJ, Hong JH, Yang S, Kim NY.
PMID: 34575688
J Pers Med. 2021 Sep 13;11(9). doi: 10.3390/jpm11090912.

The usage of dexmedetomidine during cancer surgery in current clinical practice is debatable, largely owing to the differing reports of its efficacy based on cancer type. This study aimed to investigate the effects of dexmedetomidine on biochemical recurrence (BCR)...

Cite
Yoo YC, Jang WS, Kim KJ, et al. Effect of Dexmedetomidine on Biochemical Recurrence in Patients after Robot-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Study. J Pers Med. 2021;11(9)doi: 10.3390/jpm11090912.
Yoo, Y. C., Jang, W. S., Kim, K. J., Hong, J. H., Yang, S., & Kim, N. Y. (2021). Effect of Dexmedetomidine on Biochemical Recurrence in Patients after Robot-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Study. Journal of personalized medicine, 11(9), . https://doi.org/10.3390/jpm11090912
Yoo, Young Chul, et al. "Effect of Dexmedetomidine on Biochemical Recurrence in Patients after Robot-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Study." Journal of personalized medicine vol. 11,9 (2021). doi: https://doi.org/10.3390/jpm11090912
Yoo YC, Jang WS, Kim KJ, Hong JH, Yang S, Kim NY. Effect of Dexmedetomidine on Biochemical Recurrence in Patients after Robot-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Study. J Pers Med. 2021 Sep 13;11(9). doi: 10.3390/jpm11090912. PMID: 34575688; PMCID: PMC8464875.
Copy Download .nbib Format: NLM
Ionic Salts@Metal-Organic Frameworks: Remarkable Component to Improve Performance of Fabric Filters to Remove Particulate Matters from Air.

ACS applied materials & interfaces

Yoo DK, Woo HC, Jhung SH.
PMID: 33970607
ACS Appl Mater Interfaces. 2021 May 19;13(19):23092-23102. doi: 10.1021/acsami.1c02290. Epub 2021 May 10.

The elimination of particulate matters (PMs) from the air is very important for our sustainability. In this study, highly porous metal-organic frameworks (MOFs) like MIL-101 and UiO-67 were first modified, coated onto cotton, and applied in PM removal via...

Cite
Yoo DK, Woo HC, Jhung SH. Ionic Salts@Metal-Organic Frameworks: Remarkable Component to Improve Performance of Fabric Filters to Remove Particulate Matters from Air. ACS Appl Mater Interfaces. 2021;13(19):23092-23102doi: 10.1021/acsami.1c02290.
Yoo, D. K., Woo, H. C., & Jhung, S. H. (2021). Ionic Salts@Metal-Organic Frameworks: Remarkable Component to Improve Performance of Fabric Filters to Remove Particulate Matters from Air. ACS applied materials & interfaces, 13(19), 23092-23102. https://doi.org/10.1021/acsami.1c02290
Yoo, Dong Kyu, et al. "Ionic Salts@Metal-Organic Frameworks: Remarkable Component to Improve Performance of Fabric Filters to Remove Particulate Matters from Air." ACS applied materials & interfaces vol. 13,19 (2021): 23092-23102. doi: https://doi.org/10.1021/acsami.1c02290
Yoo DK, Woo HC, Jhung SH. Ionic Salts@Metal-Organic Frameworks: Remarkable Component to Improve Performance of Fabric Filters to Remove Particulate Matters from Air. ACS Appl Mater Interfaces. 2021 May 19;13(19):23092-23102. doi: 10.1021/acsami.1c02290. Epub 2021 May 10. PMID: 33970607.
Copy Download .nbib Format: NLM
Photosynthetic symbiotic therapeutics - An innovative, effective treatment for ischemic cardiovascular diseases.

Journal of molecular and cellular cardiology

Zhu Y, Woo YJ.
PMID: 34813842
J Mol Cell Cardiol. 2021 Nov 20;164:51-57. doi: 10.1016/j.yjmcc.2021.11.007. Epub 2021 Nov 20.

Ischemic heart disease is a major cause of global morbidity and mortality, affecting over 15 million patients in the United States. Recent advances in research and innovation have greatly broadened clinicians' ability to treatment ischemic heart disease and associated...

Cite
Zhu Y, Woo YJ. Photosynthetic symbiotic therapeutics - An innovative, effective treatment for ischemic cardiovascular diseases. J Mol Cell Cardiol. 2021;164:51-57doi: 10.1016/j.yjmcc.2021.11.007.
Zhu, Y., & Woo, Y. J. (2021). Photosynthetic symbiotic therapeutics - An innovative, effective treatment for ischemic cardiovascular diseases. Journal of molecular and cellular cardiology, 16451-57. https://doi.org/10.1016/j.yjmcc.2021.11.007
Zhu, Yuanjia, and Woo, Y Joseph. "Photosynthetic symbiotic therapeutics - An innovative, effective treatment for ischemic cardiovascular diseases." Journal of molecular and cellular cardiology vol. 164 (2021): 51-57. doi: https://doi.org/10.1016/j.yjmcc.2021.11.007
Zhu Y, Woo YJ. Photosynthetic symbiotic therapeutics - An innovative, effective treatment for ischemic cardiovascular diseases. J Mol Cell Cardiol. 2021 Nov 20;164:51-57. doi: 10.1016/j.yjmcc.2021.11.007. Epub 2021 Nov 20. PMID: 34813842.
Copy Download .nbib Format: NLM
A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.

Molecular therapy. Methods & clinical development

Chaurasiya S, Yang A, Zhang Z, Lu J, Valencia H, Kim SI, Woo Y, Warner SG, Olafsen T, Zhao Y, Wu X, Fein S, Cheng L, Cheng M, Ede N, Fong Y.
PMID: 35024377
Mol Ther Methods Clin Dev. 2021 Dec 06;24:102-116. doi: 10.1016/j.omtm.2021.12.002. eCollection 2022 Mar 10.

CF33-hNIS-anti-PD-L1 is an oncolytic chimeric poxvirus encoding two transgenes: human sodium iodide symporter and a single-chain variable fragment against PD-L1. Comprehensive preclinical pharmacology studies encompassing primary and secondary pharmacodynamics and biodistribution and safety studies were performed to support the...

Cite
Chaurasiya S, Yang A, Zhang Z, et al. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer. Mol Ther Methods Clin Dev. 2021;24:102-116doi: 10.1016/j.omtm.2021.12.002.
Chaurasiya, S., Yang, A., Zhang, Z., Lu, J., Valencia, H., Kim, S. I., Woo, Y., Warner, S. G., Olafsen, T., Zhao, Y., Wu, X., Fein, S., Cheng, L., Cheng, M., Ede, N., & Fong, Y. (2022). A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer. Molecular therapy. Methods & clinical development, 24102-116. https://doi.org/10.1016/j.omtm.2021.12.002
Chaurasiya, Shyambabu, et al. "A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer." Molecular therapy. Methods & clinical development vol. 24 (2022): 102-116. doi: https://doi.org/10.1016/j.omtm.2021.12.002
Chaurasiya S, Yang A, Zhang Z, Lu J, Valencia H, Kim SI, Woo Y, Warner SG, Olafsen T, Zhao Y, Wu X, Fein S, Cheng L, Cheng M, Ede N, Fong Y. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer. Mol Ther Methods Clin Dev. 2021 Dec 06;24:102-116. doi: 10.1016/j.omtm.2021.12.002. eCollection 2022 Mar 10. PMID: 35024377; PMCID: PMC8718831.
Copy Download .nbib Format: NLM
Showing 625 to 629 of 629 entries